Cargando…

Refractory Epstein-Barr Virus (EBV)-Related Post-transplant Lymphoproliferative Disease: Cure by Combined Brentuximab Vedotin and Allogeneic EBV-Specific T-Lymphocytes

Post-transplant lymphoproliferative disease (PTLD) represents a serious complication following allogeneic hematopoietic stem cell transplantation (alloHSCT). Previously, survival rates of PTLD have improved due to the introduction of rituximab. However, reports on curative management of refractory P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mika, Thomas, Strate, Katharina, Ladigan, Swetlana, Aigner, Clemens, Schlegel, Uwe, Tischoff, Iris, Tischer-Zimmermann, Sabine, Eiz-Vesper, Britta, Maecker-Kolhoff, Britta, Schroers, Roland
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2019
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6930172/ https://www.ncbi.nlm.nih.gov/pubmed/31921871 http://dx.doi.org/10.3389/fmed.2019.00295

Ejemplares similares

Personalized adoptive immunotherapy for patients with EBV-associated tumors and complications: Evaluation of novel naturally processed and presented EBV-derived T-cell epitopes
por: Bieling, Maren, et al.
Publicado: (2017)

Dissecting Epstein-Barr Virus-Specific T-Cell Responses After Allogeneic EBV-Specific T-Cell Transfer for Central Nervous System Posttransplant Lymphoproliferative Disease
por: Schultze-Florey, Rebecca E., et al.
Publicado: (2018)

Adoptive Cell Transfer of Allogeneic Epstein–Barr Virus-Specific T Lymphocytes for Treatment of Refractory EBV-Associated Posttransplant Smooth Muscle Tumors: A Case Report
por: Hansen, Bjoern-Thore, et al.
Publicado: (2021)

Reinforcement of cell-mediated immunity driven by tumor-associated Epstein-Barr virus (EBV)-specific T cells during targeted B-cell therapy with rituximab
por: Tischer-Zimmermann, Sabine, et al.
Publicado: (2023)

Adoptive T-cell immunotherapy from third-party donors: characterization of donors and set up of a T-cell donor registry
por: Eiz-Vesper, Britta, et al.
Publicado: (2013)

Opportunities to Target the Life Cycle of Epstein-Barr Virus (EBV) in EBV-Associated Lymphoproliferative Disorders
por: Dugan, James P., et al.
Publicado: (2019)

Heat shock protein 70/peptide complexes: potent mediators for the generation of antiviral T cells particularly with regard to low precursor frequencies
por: Tischer, Sabine, et al.
Publicado: (2011)

Discovery of immunodominant T-cell epitopes reveals penton protein as a second immunodominant target in human adenovirus infection
por: Tischer, Sabine, et al.
Publicado: (2016)

Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors
por: Bonifacius, Agnes, et al.
Publicado: (2023)

High-intensity interval training in allogeneic adoptive T-cell immunotherapy – a big HIT?
por: Heinemann, Nele Carolin, et al.
Publicado: (2020)

Epstein-Barr Virus (EBV)-Related Lymphoproliferative Disorders in Ataxia Telangiectasia: Does ATM Regulate EBV Life Cycle?
por: Tatfi, Moussab, et al.
Publicado: (2019)

Establishment and operation of a Good Manufacturing Practice-compliant allogeneic Epstein-Barr virus (EBV)-specific cytotoxic cell bank for the treatment of EBV-associated lymphoproliferative disease
por: Vickers, Mark A, et al.
Publicado: (2014)

Brentuximab Vedotin
Publicado: (2012)

Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man
Publicado: (1991)

Robust Identification of Suitable T-Cell Subsets for Personalized CMV-Specific T-Cell Immunotherapy Using CD45RA and CD62L Microbeads
por: Mangare, Caroline, et al.
Publicado: (2019)

Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy: A Case Report
por: Wicklein, Rebecca, et al.
Publicado: (2021)

Choledochoduodenal Fistula during Chemotherapy with Brentuximab Vedotin for Methotrexate-associated Lymphoproliferative Disorder
por: Eso, Yuji, et al.
Publicado: (2018)

Safety and efficacy of brentuximab vedotin as a treatment for lymphoproliferative disorders in primary immunodeficiencies
por: Pincez, Thomas, et al.
Publicado: (2020)

Selective Effects of mTOR Inhibitor Sirolimus on Naïve and CMV-Specific T Cells Extending Its Applicable Range Beyond Immunosuppression
por: Bak, Szilvia, et al.
Publicado: (2018)

Adoptive Allogeneic T-Cell Therapy Improves the Clinical Outcome of JC Virus Granule Cell Neuronopathy: A Case Report
por: Grote-Levi, Lea, et al.
Publicado: (2023)

Posttransplant Lymphoproliferative Disease after Pediatric Solid Organ Transplantation
por: Mynarek, Martin, et al.
Publicado: (2013)

Inhibition of Heme Oxygenase-1 Activity Enhances Wilms Tumor-1-Specific T-Cell Responses in Cancer Immunotherapy
por: Schillingmann, Damaris A., et al.
Publicado: (2019)

Treatment Advances in EBV Related Lymphoproliferative Diseases
por: Lv, Kebing, et al.
Publicado: (2022)

641. Limited Utility of Epstein-Barr Virus (EBV) Surveillance for Predicting Post-Transplant Lymphoproliferative Disorder in EBV Seropositive Adult Lung Transplant Recipients
por: Heldman, Madeleine R, et al.
Publicado: (2023)

Allogeneic BK Virus-Specific T-Cell Treatment in 2 Patients With Progressive Multifocal Leukoencephalopathy
por: Hopfner, Franziska, et al.
Publicado: (2021)

Long-Term Follow-Up after Adoptive Transfer of BK-Virus-Specific T Cells in Hematopoietic Stem Cell Transplant Recipients
por: Koldehoff, Michael, et al.
Publicado: (2023)

Brentuximab vedotin induced uveitis
por: Therssen, Stijn, et al.
Publicado: (2022)

Leflunomide/teriflunomide inhibit Epstein-Barr virus (EBV)-induced lymphoproliferative disease and lytic viral replication
por: Bilger, Andrea, et al.
Publicado: (2017)

Hydroa vacciniforme-like lymphoproliferative disorder (HV-LPD) is an Epstein-Barr virus (EBV) associated disease()()
por: Ordoñez-Parra, Juliana, et al.
Publicado: (2021)

EBV-Positive T/NK-Cell Lymphoproliferative Disease of Childhood
por: Hong, Mineui, et al.
Publicado: (2013)

Overview of EBV-Associated T/NK-Cell Lymphoproliferative Diseases
por: Kimura, Hiroshi, et al.
Publicado: (2019)

Characterization of Epstein-Barr virus (EBV)-infected cells in EBV-associated hemophagocytic lymphohistiocytosis in two patients with X-linked lymphoproliferative syndrome type 1 and type 2
por: Yang, Xi, et al.
Publicado: (2012)

CAR-T cells and TRUCKs that recognize an EBNA-3C-derived epitope presented on HLA-B*35 control Epstein-Barr virus-associated lymphoproliferation
por: Dragon, Anna Christina, et al.
Publicado: (2020)

Epstein–Barr virus (EBV) deletions as biomarkers of response to treatment of chronic active EBV
por: Venturini, Cristina, et al.
Publicado: (2021)

Autoimmune Lymphoproliferative Syndrome and Epstein-Barr Virus-Associated Lymphoma: An Adjunctive Diagnostic Role for Monitoring EBV Viremia?
por: Pace, Romina, et al.
Publicado: (2013)

Brentuximab Vedotin in CD30+ Lymphomas
por: Perini, Guilherme Fleury, et al.
Publicado: (2013)

Brentuximab vedotin: axonal microtubule's Apollyon
por: Mariotto, S, et al.
Publicado: (2015)

Case-report: EBV driven lymphoproliferative disorder associated with Ruxolitinib
por: Pálmason, Róbert, et al.
Publicado: (2015)

Viral-Targeted Strategies Against EBV-Associated Lymphoproliferative Diseases
por: Hui, Kwai Fung, et al.
Publicado: (2019)

Challenges in Managing EBV-Associated T- and NK-Cell Lymphoproliferative Diseases
por: Sato, Yoshitaka
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1sfcop2crppoo6bgqdgsl06758